Rossari Biotech Ltd (NSE:ROSSARI)

Q4 2025 Rossari Biotech Ltd Earnings Call Transcript

Apr 28, 2025 / 11:30 AM GMT

Release Date Price: ₹690.55 (-1.26%)

Transcript

Key Points

Positve

Rossari Biotech Ltd (BOM:543213) achieved a revenue growth of 13.6% for FY25, reflecting the strength of both core and emerging businesses.
The company's HPCC division led growth with deeper market penetration and strong traction across agrochemicals, personal care, and institutional business.
Rossari Biotech Ltd (BOM:543213) is executing multiple expansion projects, with significant investments in capacity expansion to support future growth.
The company's global business recorded strong performance with exports growing by 27% and presence expanding to over 70 countries.
Rossari Biotech Ltd (BOM:543213) is focusing on innovation and sustainability, with initiatives like the Reeva biospectant platform designed for cross-sectorial impact through green chemistry.

Negative

The TSC division faced ongoing pricing pressures in the textile industry, impacting overall profitability.
Scaling up of emerging verticals has had a near-term impact on consolidated margins, with a reported EBITDA margin of 12.7% for FY25, down from 13.6% in FY24.
The company is experiencing challenges with ethylene oxide availability, which may limit growth in the HPCC segment.
Ongoing investments in new business verticals have impacted reporting margins, with increased expenses in employee costs and other operational areas.
The company's B2C and institutional businesses, while growing, are still impacting overall profitability and require further scaling to achieve positive EBITDA.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ROSB.NS - Rossari Biotech Ltd
Q4 2025 Rossari Biotech Ltd Earnings Call
Apr 28, 2025 / 11:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to Rosary Biotech Limited earnings on call.

As a reminder, all participant lines will be in the listed only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing then 0 on your touchtone phone.

Please note that this conference is being recorded.

I now have the conference over to Mr. Annoujari from CD India.

Thank you and over to you.

--------------------------------------------------------------------------------
Unidentified_2 [2]
------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.